Assume same market cap as Pharmasset,,,12 bil / 56 mil shares ~ $200 for FC,,,~$100 for long term s antigen suppression wo FC
PPS didn't hit $1, so KD is that there.
I don't think Shorts are capable or stupid enough to do that...
As is , there are not enough volume for them to cover..
Alnylam Pharmaceuticals, Inc. (ALNY), the i is for invest.
I guess that doesn't work,,,R and N not working with ALNY,,,,,Sorry shorts.
This may cause other pharma to think twice before making offer. An executive will need to think twice before making the pitch to the board.
ROCHE and NVS may think there are credible potential to the assets, which they sold to arwr, but politically management can't risk their career spending more money on iRNA.
If ARC520 can achieve a sustaining suppression of HsAg or FC (beating interferon by double digit %),
ROFN doesn't really matter in grand scheme of thing.